53 results on '"Ferraù F"'
Search Results
2. 34P Impact of environmental pollution on adrenocortical carcinoma in Italy
3. Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy
4. Global Cushing’s disease epidemiology: a systematic review and meta-analysis of observational studies
5. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
6. What we have to know about corticosteroids use during Sars-Cov-2 infection
7. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior
8. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
9. Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
10. GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly
11. Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study
12. Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden
13. Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
14. Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
15. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
16. Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8)
17. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)
18. The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease.
19. Use of the Word “Cured” for Cancer Patients—Implications for Patients and Physicians: The Siracusa Charter
20. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment
21. Implementation of adherence to erlotinib by a treatment-monitoring program.
22. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)
23. Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL
24. 50 IMPLEMENTATION OF ADHERENCE TO ERLOTINIB (E) AS SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
25. Increased prevalence of acromegaly in a highly polluted area
26. PO-71 Low molecular weight heparin (LMWH) administration in cancer patients (PTS) with hypercoagulability related complications and carrying brain metastases: a case series
27. Scientific Activity and Needs Among Medical Oncology Units in Sicily: A Survey of The Italian Association of Medical Oncology
28. Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormonesecreting adrenal phaeochromocytoma: review of the literature and report of a case
29. First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small cell lung cancer: A randomized phase II trial of the Gruppo Oncologico Italia Meridionale
30. Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
31. Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormonesecreting adrenal phaeochromocytoma: review of the literature and report of a case
32. Activity and tolerability of Cisplatin (CDDP) and Fotemustine (FTM) combination in the treatment of patients with non-small cell lung cancer (NSCLC) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
33. First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small-cell lung cancer: A phase II randomized trial of Gruppo Oncologico Italia Meridionale
34. P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study
35. Induction chemotherapy with carboplatin (C), paclitaxel (P) and gemcitabine (G) in unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC). A phase I-II study
36. Short course dose-dense (dd) epirubicin (E) and cyclophosphamide (C) as neo-adjuvant chemotherapy for stage II-IIIA breast cancer (BC)
37. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomised phase II trial
38. Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer
39. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
40. PO-47 Low molecular weight heparin (LMWH) administration in patients suffering from pulmonary embolism and brain metastases (mts): a report of two cases
41. Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas
42. Locally advanced non-small cell lung cancer: different strategies for different diseases
43. Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study
44. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
45. Metastasis to the thyroid gland: A case report and review of the literature
46. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
47. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer
48. I tumori del rachide
49. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
50. Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.